While early weight loss is a valuable predictor, it does not fully explain the factors determining individual response to treatment
This binding extends its half-life dramatically, which is why a single weekly injection maintains therapeutic levels for seven full days
More recently, ketogenic diets have shown potential in modulating insulin signaling and inflammatory pathways, though clinical evidence remains limited
Most states either completed unwinding redeterminations by FY 2024 (two-thirds of states) or by midway through FY 2025 (another one-sixth of states), with the remainder noting their redeterminations continued through the second half of FY 2025 or would continue into FY 2026
Clinical studies of semaglutide and tirzepatide show average weight loss of 15-24% over extended periods, though individual results vary significantly
If you have any questions about your results or your screening plan, contact your provider over the phone or using the secure messaging feature in MyChart